EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association between bisphosphonate use and COVID-19 related outcomes

Jeffrey Thompson, Yidi Wang, Tobias Dreischulte, Olga Barreiro, Rodrigo J Gonzalez, Pavel Hanč, Colette Matysiak, Harold R Neely, Marietta Rottenkolber, Thomas Haskell, Stefan Endres iD, Ulrich H von Andrian iD

eLife · 03.08.2023 · 12

DOI: 10.7554/elife.79548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 03.08.2023. Verfasst von Jeffrey Thompson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cerner Enviza, Malvern, United States. Hauptthemen laut MEDLINE: COVID-19, Respiratory Tract Infections, Bronchitis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research Institute, NIAID NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although there are several efficacious vaccines against COVID-19, vaccination rates in many regions around the world remain insufficient to prevent continued high disease burden and emergence of viral variants. Repurposing of existing therapeutics that prevent or mitigate severe COVID-19 could help to address these challenges. The objective of this study was to determine whether prior use of bisphosphonates is associated with reduced incidence and/or severity of COVID-19.

Methods

A retrospective cohort study utilizing payer-complete health insurance claims data from 8,239,790 patients with continuous medical and prescription insurance January 1, 2019 to June 30, 2020 was performed. The primary exposure of interest was use of any bisphosphonate from January 1, 2019 to February 29, 2020. Bisphosphonate users were identified as patients having at least one bisphosphonate claim during this period, who were then 1:1 propensity score-matched to bisphosphonate non-users by age, gender, insurance type, primary-care-provider visit in 2019, and comorbidity burden. Main outcomes of interest included: (a) any testing for SARS-CoV-2 infection; (b) COVID-19 diagnosis; and (c) hospitalization with a COVID-19 diagnosis between March 1, 2020 and June 30, 2020. Multiple sensitivity analyses were also performed to assess core study outcomes amongst more restrictive matches between BP users/non-users, as well as assessing the relationship between BP-use and other respiratory infections (pneumonia, acute bronchitis) both during the same study period as well as before the COVID outbreak.

Results

A total of 7,906,603 patients for whom continuous medical and prescription insurance information was available were selected. A total of 450,366 bisphosphonate users were identified and 1:1 propensity score-matched to bisphosphonate non-users. Bisphosphonate users had lower odds ratios (OR) of testing for SARS-CoV-2 infection (OR = 0.22; 95%CI:0.21–0.23; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Respiratory Tract InfectionsBronchitisHumansDiphosphonatesCOVID-19 TestingSARS-CoV-2Retrospective StudiesCOVID-19 VaccinesProspective Studies

Stichwörter der Autor:innen

BisphosphonateCOVID-19epidemiologyglobal healthhumanmedicineretrospective cohort study

Substanzen

DiphosphonatesCOVID-19 Vaccines

Autor:innen und Institutionen

  • Cerner Enviza, Malvern, United States.
  • Dept. of Immunology, Harvard Medical School, Boston, United States.
  • Institute of General Practice and Family Medicine, University Hospital of Ludwig Maximilians-University Munich, Munich, Germany.
  • Center of Integrated Protein Science Munich and Division of Clinical Pharmacology, University Hospital, LMU Munich, Germany, Munich, Germany.

ORCID-Profile: Stefan Endres, Ulrich H von Andrian

Förderung

  • Cancer Research Institute
  • NIAID NIH HHS
  • NIAMS NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • MassCPR

Zitieren

APA

Thompson, J., Wang, Y., Dreischulte, T., Barreiro, O., Gonzalez, R. J., Hanč, P., Matysiak, C., Neely, H. R., Rottenkolber, M., Haskell, T., Endres, S., & von Andrian, U. H. (2023). Association between bisphosphonate use and COVID-19 related outcomes. eLife, 12. https://doi.org/10.7554/elife.79548

Vancouver

Thompson J, Wang Y, Dreischulte T, Barreiro O, Gonzalez RJ, Hanč P, et al. Association between bisphosphonate use and COVID-19 related outcomes. eLife. 2023;12. doi:10.7554/elife.79548

BibTeX
@article{Thompson2023,
  author = {Thompson, Jeffrey and Wang, Yidi and Dreischulte, Tobias and Barreiro, Olga and Gonzalez, Rodrigo J and Hanč, Pavel and Matysiak, Colette and Neely, Harold R and Rottenkolber, Marietta and Haskell, Thomas and Endres, Stefan and von Andrian, Ulrich H},
  title = {Association between bisphosphonate use and COVID-19 related outcomes},
  journal = {eLife},
  year = {2023},
  volume = {12},
  doi = {10.7554/elife.79548}
}
Kostenlos starten →